{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":81},"studies":[{"active":true,"description":"International, multicenter, non-interventional PASS study  to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings","eudractNumber":null,"id":11259,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T10:04:25+02:00","shortTitle":"MagnetisMM-16","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

ENCLOSE (Klinische Studiengruppe NAFLD): CK18 M30 als\nnicht-invasiver Marker für subklinische Zellschädigung – prospektive Analyse\ndes Langzeitverlaufes bei NAFLD

","eudractNumber":null,"id":2266,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[{"name":"Caspase-cleaved fragment of CK18 (M30)","id":"mt_271"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-07-01T14:19:23+02:00","shortTitle":"NAFLD CSG","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Multizentrische, länderübergreifende, prospektive, beobachtende Unbedenklichkeitsstudie zur Beschreibung der Inzidenz der Abbruchquote aufgrund von Diarrhoe innerhalb der ersten 3 Monate der Behandlung mit Neratinib bei erwachsenen Brustkrebspatienten als erweiterte adjuvante Behandlung in einem realen Umfeld: die NERLYFE-Studie","eudractNumber":null,"id":9352,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-10T10:14:43+02:00","shortTitle":"NERLYFE-Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Dieses Single Patient\nRequest (SPR) / Named Patient Program (NPP) / Intermediate Expanded Access\nProgram (I-EAP) soll einen frühzeitigen Zugang zu\nNiraparib/Abirateronacetat-Kombination (JNJ- 67652000) zur Anwendung mit\nPrednison oder Prednisolon vor der Zulassung ermöglichen, um einen kritischen\nungedeckten Bedarf bei Patienten mit Prostatakrebs zu decken, die ein\nmetastasiertes kastrationsresistentes Prostatakarzinom (mCRPC) entwickelt haben\nund bei denen homologe Rekombinationsreparatur (HRR)-Genveränderungen (Keimbahn\nund/oder somatisch) positiv sind.","eudractNumber":null,"id":7946,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-14T16:19:57+02:00","shortTitle":"NPP 67652000MPC4001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Treatment and outcome of patients with advanced breast cancer: clinical research platform for real world data (OPAL) IOM-100361","eudractNumber":null,"id":4638,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT03417115","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-05-03T12:36:45+02:00","shortTitle":"OPAL (IOM-100361)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":9703,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-15T08:27:15+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":10857,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-04-01T08:48:22+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":4307,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-01-03T12:47:13+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":10618,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-08-05T09:22:14+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":4571,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-02T13:28:48+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]}]},"initialUrl":"/api/studies?lang=de&page=4&pfs=ph_2&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"International, multicenter, non-interventional PASS study  to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings\",\"name\":\"MagnetisMM-16\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11259\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

ENCLOSE (Klinische Studiengruppe NAFLD): CK18 M30 als\\nnicht-invasiver Marker für subklinische Zellschädigung – prospektive Analyse\\ndes Langzeitverlaufes bei NAFLD

\",\"name\":\"NAFLD CSG\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/2266\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Multizentrische, länderübergreifende, prospektive, beobachtende Unbedenklichkeitsstudie zur Beschreibung der Inzidenz der Abbruchquote aufgrund von Diarrhoe innerhalb der ersten 3 Monate der Behandlung mit Neratinib bei erwachsenen Brustkrebspatienten als erweiterte adjuvante Behandlung in einem realen Umfeld: die NERLYFE-Studie\",\"name\":\"NERLYFE-Studie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9352\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Dieses Single Patient\\nRequest (SPR) / Named Patient Program (NPP) / Intermediate Expanded Access\\nProgram (I-EAP) soll einen frühzeitigen Zugang zu\\nNiraparib/Abirateronacetat-Kombination (JNJ- 67652000) zur Anwendung mit\\nPrednison oder Prednisolon vor der Zulassung ermöglichen, um einen kritischen\\nungedeckten Bedarf bei Patienten mit Prostatakrebs zu decken, die ein\\nmetastasiertes kastrationsresistentes Prostatakarzinom (mCRPC) entwickelt haben\\nund bei denen homologe Rekombinationsreparatur (HRR)-Genveränderungen (Keimbahn\\nund/oder somatisch) positiv sind.\",\"name\":\"NPP 67652000MPC4001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7946\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Treatment and outcome of patients with advanced breast cancer: clinical research platform for real world data (OPAL) IOM-100361\",\"name\":\"OPAL (IOM-100361)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/4638\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
\",\"name\":\"PCO-D Studie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9703\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
\",\"name\":\"PCO-D Studie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10857\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
\",\"name\":\"PCO-D Studie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/4307\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
\",\"name\":\"PCO-D Studie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10618\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
\",\"name\":\"PCO-D Studie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/4571\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=5&pfs=ph_2\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}